Tweet
Thank You Marianne - for posting this at the Cushings forum.
____________
VETORYL (TRILOSTANE) RECEIVES FDA APPROVAL
OVERLAND PARK, KS, DECEMBER 15, 2008 – Dechra Veterinary Products LLC today announces that the company has received FDA approval to market VETORYL Capsules.
VETORYL Capsules contain the drug trilostane, which has been demonstrated to be effective in the treatment of Cushing's syndrome in dogs. VETORYL will be indicated for use in pituitary-dependent hyperadrenocorticism, which comprises the majority of cases
of Cushing's syndrome in dogs. Additionally, VETORYL has received designation status as a Minor Use Drug for treatment of hyperadrenocorticism caused by adrenal tumors – the first drug to receive an approval for this indication and the first drug to receive a
Minor Use designation in dogs.
Mike Eldred, President of U.S. Operations, says, “We are very excited to have approval to market this novel product in the U.S. Following its launch in January, veterinarians will be able to source the product through our network of distribution partners.”
Dechra Veterinary Products LLC, located in Overland Park, Kansas, is the U.S. subsidiary of Dechra Pharmaceuticals PLC, a UK listed company focused on international animal healthcare markets. Dechra currently markets a range of specialized veterinary products in the U.S. For more information, please visit www.dechra-us.com or call 866-933-2472.
Product photos available by request. Please call Phil Hermanson at 785-838-4774, or email at phermanson@callahancreek.com.
Contact:
Mike Eldred
President U.S. Operations
Dechra Veterinary Products
(913) 748-4830
mike.eldred@dechra.com
Doug Hubert
Sales and Marketing Director
Dechra Veterinary Products
(913) 748-4831
doug.hubert@dechra.com
____________
VETORYL (TRILOSTANE) RECEIVES FDA APPROVAL
OVERLAND PARK, KS, DECEMBER 15, 2008 – Dechra Veterinary Products LLC today announces that the company has received FDA approval to market VETORYL Capsules.
VETORYL Capsules contain the drug trilostane, which has been demonstrated to be effective in the treatment of Cushing's syndrome in dogs. VETORYL will be indicated for use in pituitary-dependent hyperadrenocorticism, which comprises the majority of cases
of Cushing's syndrome in dogs. Additionally, VETORYL has received designation status as a Minor Use Drug for treatment of hyperadrenocorticism caused by adrenal tumors – the first drug to receive an approval for this indication and the first drug to receive a
Minor Use designation in dogs.
Mike Eldred, President of U.S. Operations, says, “We are very excited to have approval to market this novel product in the U.S. Following its launch in January, veterinarians will be able to source the product through our network of distribution partners.”
Dechra Veterinary Products LLC, located in Overland Park, Kansas, is the U.S. subsidiary of Dechra Pharmaceuticals PLC, a UK listed company focused on international animal healthcare markets. Dechra currently markets a range of specialized veterinary products in the U.S. For more information, please visit www.dechra-us.com or call 866-933-2472.
Product photos available by request. Please call Phil Hermanson at 785-838-4774, or email at phermanson@callahancreek.com.
Contact:
Mike Eldred
President U.S. Operations
Dechra Veterinary Products
(913) 748-4830
mike.eldred@dechra.com
Doug Hubert
Sales and Marketing Director
Dechra Veterinary Products
(913) 748-4831
doug.hubert@dechra.com
Comment